Exostemtech, a "exosome treatment," attracts 10 billion won in series B investment (Korea economy)
- Oct 26, 2021
- 1 min read
Updated: Sep 28, 2022
Exostemtech, a bio-venture specializing in the development of exosome-based treatments, announced on the 26th that it has attracted 10 billion won worth of Series B investment.
▲ DSC Investment ▲ IMM Investment ▲ We Ventures ▲ Laguna Investment ▲ Hana Financial Investment participated in this investment.
Exostemtech is a bio-venture that develops various treatments for intractable diseases based on exosomes. Exosomes are extracellular vesicles measuring 30 to 150 nanometers (nm) that serve to transfer information between cells. Exosome-based new drugs are used for anti-inflammatory, anti-aging, and tissue regeneration due to their excellent drug delivery ability and regenerative treatment. The company has developed a degenerative arthritis treatment "CARTISOME," a liver fibrosis treatment "HEPATOSOME," and a cancer exosome inhibitor "EST-SFX-T" using exosomes to promote clinical trials.
Comments